Eisai is winding down a co-promotion deal with Pfizer and shifting toward a lean commercial structure it says will thrust it into the top 10 in women’s oncology.
Forest Labs to acquire Clinical Data, add reps for Viibryd launch
Forest Labs will acquire Clinical Data for $1.2 billion, and expand its primary care sales forces in preparation for the launch of Viibryd (vilazodone HCI), executives said in a call this morning.
Sunovion Pharmaceuticals is targeting 22,000 psychiatrists in the US, with a sales force of 336 reps, in support of Latuda, an atypical antipsychotic for the treatment of schizophrenia. Psychiatrists can also request samples and track delivery online.
GSK and HGS put the ‘us’ in lupus, ahead of Benlysta FDA decision
GlaxoSmithKline and Human Genome Sciences launched a patient community for lupus sufferers and their friends and family, in anticipation of an FDA decision on Benlysta in March.
New depression med hopes to grab a piece of the $12 billion pie
With depression brand leaders Cymbalta and Lexapro closing in on patent expiry, Clinical Data’s newly approved Viibryd (vilazodone HCI) for major depressive disorders hopes to carve out a piece of the roughly $12 billion US market.
Sales reps armed with an iPad can collect digital signatures for samples thanks to iRep, a physician detailing application set to launch in mid-February.
Pfizer hypes Advil line extension with TV ad, personal shopper offer
Pfizer Consumer Healthcare is launching an Advil line extension with a contest to win a personal shopper for “Black Friday,” the Friday after Thanksgiving, when bargain-hunting holiday shoppers pack stores.
The American Association for Cancer Research will launch a new journal — Cancer Discovery — in April 2011. The peer-reviewed journal will focus on research spanning cancer science and medicine, including news, commentaries, and “Research Watch” summaries of important journal articles.
P&G, Somaxon deploy reps and e-detailing for Silenor launch
Proctor & Gamble and Somaxon Pharmaceuticals have deployed 215 reps in support of Silenor (doxepin), a newly approved sleep aid indicated for sleep maintenance. E-detailing programs will also launch this quarter.
Kowa’s US CEO says new statin holds appeal for untreated patients
To those who believe we have everything we need in the lipid-lowering world, Ben Stakely, Kowa Pharmaceuticals America (KPA) CEO and president, has one thing to say: “I would argue with you.”